Impact of Magnesium Oxide Nanoparticles on Erythropoietin Hormone Levels in Sera of Patients with Anemia Accompanied with Diabetic Kidney Disease

Ameer Radhi Sultan\(^1\), Fatin Fadhel Mohammed Al-Kazazz\(^1\), Asma Hadi Mohammed\(^2\)

\(^1\)Department of Chemistry, College of Science, Al-Mustansiriya University, Iraq.
\(^2\)Department of Physics, College of Science, Al-Mustansiriya University, Iraq.

Received: Apr. 13, 2020; Accepted: Jul. 21, 2020; Published: Aug. 25, 2020


Abstract

The present research aimed to study the clinical efficacy of novel of impact of magnesium oxide nanoparticles on erythropoietin hormone in blood. Magnesium oxide nanoparticles (MgO NPs) were prepared by the chemical method. The synthesized nanoparticles were diagnosed via X-ray diffraction (XRD) and transmission electron microscopy (TEM). The average particle size was 10.8-12.6 nm. Blood samples were collected from 68 samples, classified as 24 patients with diabetic, 24 patients with diabetic kidney disease, and a control group of 20 healthy males. The age for all groups ranged between 34-72 years old. For evaluating the effectiveness of the erythropoietin (EPO) hormone with MgO NPs, the results showed a significant increase in the level of erythropoietin hormone with MgO NPs compared with the level of erythropoietin hormone without MgO NPs in patients with diabetic kidney disease (DKD). The activating percentage of erythropoietin hormone action was 84.8%. In conclusion, magnesium oxide nanoparticles may exhibit an impact on erythropoietin hormone and its receptor thus improving the “action”, i.e. the binding and interaction between the hormone EPO and its receptors forming their complex. Therefore, the biochemical effects and physiological effects would be more controlled and regulated, thus increasing the level of hemoglobin in the blood and reducing the anemia state.

Keywords: Binding; DKD; MgO NPs; XRD; TEM; EPO

Introduction

Chronic kidney disease (CKD) has been present for more than 3 months as an abnormality in kidney functions as a result of deteriorating kidney structure and glomerular filtration rate (GFR) [1]. Diabetic kidney disease (DKD) also previously known as diabetic nephropathy (DN) usually occurs in type 1 and type 2 diabetes mellitus (DMT1, DMT2) patients. It is defined depending on change of renal function and structure that includes the thickening of the membrane in the glomerular and tubular basement and glomerular sclerosis lead to CKD [2]. Type 2 diabetes is the most cause of DKD and chronic renal failure. In the United States, about 40% of the 29 million people with type 2 diabetes have DKD [3]. Anemia is a complication
of chronic kidney disease and high patient mortality is associated with an increased outcome of anemia caused by kidney failure as the main cause of anemia in CKD is a deficiency of the erythropoietin hormone [4].

Erythropoietin (EPO) is a glycoprotein hormone that consists of 165 amino acids. It is synthesized via the kidneys and stimulates the bone marrow to produce erythrocytes [5]. Although adequate doses of the recombinant human EPO (rhuEPO) were given as a treatment, the patient still suffered from anemia [6]. Most patients with CKD have resistance to rhuEPO treatment, so they need a high dose of rhuEPO. This dose can cause harmful effects, such as high blood pressure, heart disease and thrombosis. Hence, safer and more efficient strategies for treating anemia must be found [7].

Nanotechnology is the science that enables the development of new nano materials within a nanoscale of less than 100 nm. It is widely used in all fields because of the unique and featured physical and chemical properties of nano materials [8-19]. Nanoparticles (NPS) have new and important properties due to their small size and high surface area. There are numerous nanoparticles oxides which are known for their widespread use as drug delivery and treatment [20]. Magnesium oxide (MgO) is an important essential metal oxide among various metal oxides due to versatile applications that are influenced by specific magnetic, electrical, thermal and chemical properties [21]. There has been extensive study of magnesium oxide NPs for antibacterial function, drug delivery, diagnosis and anticancer [22]. Loading the drug with nanoparticles gives the advantage like reducing side effects, targeted delivery, protecting the drug from degradation and having prolonged drug release [23]. Proteins are functionally important biomolecules, and protein binding of NPs has found critical applications in the catalysis and perception of protein structural modifications [24]. Most proteins improve the internalization of NPs into cells by interacting directly with their receptors on cell membranes [25]. The size and shape of the MgO NPs created in the research, along with other beneficial properties of MgO NPs, encouraged us to use them as an enhancer for the effectiveness of the EPO hormone.

**Experimental**

**Chemicals**

Magnesium nitrate Mg(NO$_3$)$_2$ and sodium hydroxide (NaOH) were obtained from BDH, England and Barcelona, Spain respectively. Polyvinyl pyrrolidone (C$_6$H$_9$NO) and sodium hydrogen carbonate were obtained from Sigma-Aldrich, Germany.

**Parameters assays**

Kits of urea, creatinin, glucose, albumin, total protein, magnesium, vitamin B$_{12}$, folic acid, iron, total iron-binding capacity (TIBC), unsaturated iron-binding capacity (UIBC), ferritin, hemoglobin, and cytomegalovirus (CMV) were supplied and measured by Abbott / Architect Instrument. Erythropoietin hormone kit was supplied by Human, German Company and measured by Elisa / Epson Instrument.

**Preparation of MgO nanoparticles**

Co-precipitation method was used to prepare MgO nanoparticles. Mg(NO$_3$)$_2$ of 1 M was dissolved with polyvinylpyrrolidone (PVP) by 50 mL of deionized water. Solution of NaHCO$_3$ (1 M) was added to a mixture solution of Mg(NO$_3$)$_2$ and PVP under stirring at 26 °C. Then, 1 M of NaOH solution was slowly added to the mixture above. The white precipitate was separated and washed several times with deionized water, then dried for 1 h at 80 °C and calcinated at 350 °C for 3 h. The white powder of MgO NPs was obtained [26].

**Subjects, samples collection and preparation samples**

About 5 mL of venous blood samples were taken from 68 samples classified to 24 male patients with diabetic, 24 male patients with DKD at stage 3 - 4 and 20 male healthy as control, the age for all groups ranging between 34 - 72 years old. For the purpose of studying the effect of MgO NPs in vitro on the EPO hormone, the group of patients with DKD was divided into before and after the addition of MgO NPs to the serum patients. All patients and healthy subjects were fasted for approximately 12 h before drawing blood.

**Determination of serum EPO hormone level by the ELISA kit**

Erythropoietin hormone immunoassay was used for the quantitative measurement of EPO hormone in human serum (sandwich method). This parameter was based on the immobilization of anti-erythropoietin hormone antibodies to the solid phase of the well and binding of EPO from patient serum. The bound EPO was detected with horseradish peroxidase-labeled secondary antibody that was directed with human.
EPO. Concentrations of standard (calibrator) of EPO kit were: 0, 10.2, 25.2, 48.8, 146 and 448 IU/L. The method involved adding 200 μL of DDW, 200 μL of calibrator, 200 μL of control positive and negative and 175 μL of serum samples + 25 μL of DDW into wells to determine EPO either without MgO NPs or with the presence of MgO NPs (by adding 175 μL of serum samples to 25 μL of MgO NPs). A 25 μL of biotinylated antibody and 25 μL of peroxidase-labeled secondary antibody sequentially were added to all wells. The plate was incubated in the dark at 24 °C for 2 h with shaking. After the plate was washed 5 times with 0.35 μL of wash solution, 150 μL of tetramethylbenzidine was added to the wells except the blank well and incubated at 24 °C for 30 min with shaking. 100 μL of the solution was added to all wells except the blank well. After the reaction was completed, the samples were read at a wavelength of 450 nm.

**Statistical test**

SPSS version 24 statistical Microsoft office was used for our research data, which included mean ± standard deviation (SD), non-significance was defined as p-value ≥ 0.05, while p-value ≤ 0.05 was considered significant, with r = correlation coefficient analysis that was applied to evaluate the relationship between bio tests. The results were analyzed by one-way ANOVA.

**Results and Discussion**

**Characterization of Mgo NPs**

The instrument measuring X-ray diffraction patterns of pure magnesium oxide nanoparticles was Shimadzu X-RD diffractometer, type X-RD-6000. The sample appeared in a hexagonal and cube shape according to major peaks seen at 2θ = 36.8°, 42.8°, 62.1°, 74.7° and 78.4° matching miller indices which include (111), (200), (220), (311) and (222) based on JCPDS PDF 0045-0946 (Fig. 1). The average size of crystallite calculated according to Scherrer formula was 10 nm, as in Equation (1).

\[ D = \frac{k\lambda}{\beta \cos \theta}, \]

where k = 0.9 was Scherrer constant, \( \lambda = 0.154 \text{ nm} \) referred to wavelength of the source radiations, \( \beta \) was considered width at half maximum, and \( \theta \) was angle of the bragg peak.

The shape of the MgO NP was also studied with transmission electron microscopy (TEM) images as seen in Fig. 2. The morphology of the pure MgO NPs was described as spherical. The average particles size of MgO NPs were calculated randomly from the TEM figures and ranged between 10.8 and 12.6 nm.

**Diagnosis of kidney function and anemia associated with DKD**

Kidney function was evaluated by estimating the level of urea, creatinine and GFR, and by detecting anemia through estimating the levels of EPO hormone and hemoglobin, in addition to other tests affected by chronic kidney failure as listed in Table 1.

There were a highly significant increase in serum
levels of glucose, urea, creatinine, a highly significant decrease in serum levels of total protein, albumin, magnesium, iron, sat%, EPO, blood hemoglobin and GFR in patients with DKD compared to the control group (p < 0.01), and a significant decrease in the levels of MCV and TIBC (p < 0.05). The results also showed a non-significant decrease in the levels of UIBC, ferritin, folic acid and vitamin B₁₂ in patients with DKD compared to the control group (p > 0.05).

The results also showed a highly significant increase in the serum levels of glucose, urea, creatinine, a highly significant decrease in the serum levels of EPO, ferritin, blood hemoglobin and GFR, and a significant decrease in the serum levels of total protein, albumin, iron, TIBC and sat%. The results also showed non-significant decrease in the levels of magnesium, folic acid, vitamin B₁₂, UIBC and blood MCV in patients with DKD compared to patients with DMT2.

### Study of MgO NPs on EPO hormone levels of patients with DKD in vitro

According to the results shown in Table 2, there was a highly significant decrease in the serum level of EPO hormone in DKD patients without MgO NPs and DKD patients with MgO NPs, compared to patients diabetes type 2 (p < 0.01). Also, there was a significant increase in the levels of EPO hormone in DKD patients with MgO NPs compared to EPO DKD patients without MgO NPs (p < 0.05). The activation percentages of EPO hormone was 84.8%, which was calculated by comparing the EPO hormone concentration with and without MgO NPs, as in Equation (2) [27].

\[
\% \text{ Activation} = 100 \times \frac{[\text{EPO hormone with MgO NPs}]}{[\text{EPO hormone without MgO NPs}]} - 100
\]

Thus, % Activation = 100 × (6.11 / 3.31) - 100 = 84.8%.

### Table 1  Serum bio tests of patients with DMT2, DKD at stage 3 - 4 and the control group

<table>
<thead>
<tr>
<th>Biotest</th>
<th>Control, n = 20</th>
<th>Patients with diabetes mellitus (DM), n = 24</th>
<th>Patients with diabetic nephropathy (DN), n = 24</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. glucose (mg/dL)</td>
<td>80.83 ± 13.09a</td>
<td>135.62 ± 10.71b</td>
<td>147.25 ± 11.96b</td>
<td>a&amp;b, c, b&amp;c</td>
</tr>
<tr>
<td>S. urea (mg/dL)</td>
<td>29.12 ± 1.78a</td>
<td>30.39 ± 2.41b</td>
<td>101.74 ± 17.39a</td>
<td>a&amp;b, b&amp;c, c</td>
</tr>
<tr>
<td>S. creatinine (mg/dL)</td>
<td>0.55 ± 0.03a</td>
<td>0.58 ± 0.03b</td>
<td>3.14 ± 0.79a</td>
<td>a&amp;b, b&amp;c, c</td>
</tr>
<tr>
<td>GFR (mL/min per 1.73 m²)</td>
<td>97.47 ± 10.59a</td>
<td>89.38 ± 20.77b</td>
<td>31.85 ± 11.38c</td>
<td>a&amp;b, b&amp;c, c</td>
</tr>
<tr>
<td>S.T. protein (g/dL)</td>
<td>6.91 ± 0.33a</td>
<td>6.75 ± 0.37b</td>
<td>6.44 ± 0.51a</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>S. albumine (mg/dL)</td>
<td>4.23 ± 0.26a</td>
<td>4.04 ± 0.45a</td>
<td>3.69 ± 0.6a</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>S. magnesium (mg/dL)</td>
<td>2.34 ± 0.12a</td>
<td>2.2 ± 0.14a</td>
<td>2.11 ± 0.19a</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>S. EPO (IU/L)</td>
<td>24.53 ± 5.07a</td>
<td>21.27 ± 5.8b</td>
<td>3.31 ± 1.08a</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>14.27 ± 0.97a</td>
<td>13.86 ± 0.89b</td>
<td>10.52 ± 0.78b</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>MCV (f/L)</td>
<td>83.43 ± 3.26a</td>
<td>80.87 ± 2.95b</td>
<td>79.2 ± 7.14a</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>S. iron (µg/dL)</td>
<td>113.1 ± 23.88a</td>
<td>106.87 ± 24.53b</td>
<td>86.96 ± 22.79b</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>S. TIBC (µg/dL)</td>
<td>337.05 ± 26.64a</td>
<td>334.04 ± 33.83b</td>
<td>308.75 ± 41.37b</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>UIBC (µg/dL)</td>
<td>224.4 ± 11.77a</td>
<td>219.57 ± 45.1b</td>
<td>221.74 ± 33.85b</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>Sat%</td>
<td>34.62 ± 4.07a</td>
<td>31.98 ± 5.42a</td>
<td>27.64 ± 6.29a</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>S. ferritin (ng/mL)</td>
<td>57.16 ± 9.43a</td>
<td>62.01 ± 10.26b</td>
<td>52.02 ± 8.64a</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>S. folic acid (ng/mL)</td>
<td>8.66 ± 1.34a</td>
<td>8.35 ± 1.21b</td>
<td>8.24 ± 1.59a</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
<tr>
<td>S. vitamin B₁₂ (pg/mL)</td>
<td>654.9 ± 80.36a</td>
<td>644.58 ± 66.91b</td>
<td>598.5 ± 56.89b</td>
<td>a&amp;b, a&amp;c, b&amp;c</td>
</tr>
</tbody>
</table>

Note: P ≥ 0.05 (non-significant), P ≤ 0.05 (significant), P < 0.01 (highly significant).
a: The first group, i.e. control.
b: The second group, i.e. patients with DM.
c: The third group, i.e. patients with DKD.
MCV = mean corpuscular volume; TIBC = total iron binding capacity; UIBC = unsaturated iron binding capacity calculated by S.TIBC-S.iron; Sat% = iron saturation percentage calculated by ([S.iron / S.TIBC] × 100); S = serum.
Correlation study for EPO hormone levels in sera of patients with DKD

Serum EPO hormone level was selected as the principal variable which was correlated with all biotests under this study. The correlation coefficient r and p-value are listed in Table 3. There was a strong positive relationship between the levels of EPO without MgO NPs and with hemoglobin and GFR (r = 0.56, r = 0.54) respectively, yet a moderate negative relationship for urea and creatinine (r = -0.46, r = -0.45), respectively. The levels of EPO were detected without MgO NPs in sera of patients with DKD, as shown in Fig. 3.

Fig. 3 shows a moderate positive relationship was observed between EPO with MgO NPs and hemoglobin based on r = 0.41, and there was no relationship between EPO with MgO NPs and urea, creatinine and GFR in patients with DKD.

In our current study, the effect of MgO NPs was studied on erythropoietin hormone in vitro. It was shown that there were major effects on improving and activating erythropoietin hormone action (Table 2) by about 84.8%.

Panjeta et al. [28] observed that there were a highly significant increase in creatinine level and a highly significant decrease in GFR, hemoglobin and EPO hormone level in CRF patients stage 2 – 4, compared to normal controls, which is consistent with our research results.

The relationship between biotests (Table 3) and EPO in sera patients of DKD was determined with and without MgO NPs, where only a relationship appeared between EPO without MgO NPs and hemoglobin, urea, creatinine, and GFR, while only a relationship appeared between EPO with MgO NPs and hemoglobin in sera of patients with DKD. Fig. 4 shows that there

### Table 2 Level of serum EPO hormone before and after the addition of MgO NPs into the serum of patients with DKD

<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>Serum EPO (IU/L)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean ± SD</td>
<td></td>
</tr>
<tr>
<td>Patients diabetes type 2</td>
<td>24</td>
<td>21.27 ± 5.8</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Patients DKD without MgO NPs</td>
<td>24</td>
<td>3.31 ± 1.08</td>
<td></td>
</tr>
<tr>
<td>Patients diabetes type 2</td>
<td>24</td>
<td>21.27 ± 5.8</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Patients DKD With MgO NPs</td>
<td>24</td>
<td>6.12 ± 1.94</td>
<td></td>
</tr>
<tr>
<td>Patients DKD without MgO NPs</td>
<td>24</td>
<td>3.31 ± 1.08</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Patients DKD with MgO NPs</td>
<td>24</td>
<td>6.12 ± 1.94</td>
<td></td>
</tr>
</tbody>
</table>

Note: P ≤ 0.05 considered significant; p ≤ 0.01 considered highly significant.

### Table 3 Correlation coefficient r and p-value for correlation study between biotest and EPO level (with MgO NPs and without MgO NPs)

<table>
<thead>
<tr>
<th>Biotests</th>
<th>EPO without MgO NPs</th>
<th>EPO with MgO NPs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>r</td>
<td>P-value</td>
</tr>
<tr>
<td>Glucose</td>
<td>0.060</td>
<td>0.779</td>
</tr>
<tr>
<td>Urea</td>
<td>-0.46</td>
<td>0.023</td>
</tr>
<tr>
<td>Creatinine</td>
<td>-0.45</td>
<td>0.026</td>
</tr>
<tr>
<td>GFR</td>
<td>0.54</td>
<td>0.006</td>
</tr>
<tr>
<td>Total Protein</td>
<td>-0.101</td>
<td>0.637</td>
</tr>
<tr>
<td>Albumine</td>
<td>-0.113</td>
<td>0.598</td>
</tr>
<tr>
<td>Magnesium</td>
<td>0.317</td>
<td>0.132</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>0.56</td>
<td>0.005</td>
</tr>
<tr>
<td>MCV</td>
<td>0.114</td>
<td>0.595</td>
</tr>
<tr>
<td>S. iron</td>
<td>-0.119</td>
<td>0.578</td>
</tr>
<tr>
<td>S. TIBC</td>
<td>-0.060</td>
<td>0.780</td>
</tr>
<tr>
<td>UIBC</td>
<td>0.007</td>
<td>0.973</td>
</tr>
<tr>
<td>Sat%</td>
<td>-0.142</td>
<td>0.509</td>
</tr>
<tr>
<td>Ferritin</td>
<td>0.074</td>
<td>0.731</td>
</tr>
<tr>
<td>Folic acid</td>
<td>0.066</td>
<td>0.760</td>
</tr>
<tr>
<td>Vitamin B12</td>
<td>0.042</td>
<td>0.847</td>
</tr>
</tbody>
</table>
was a strong positive relationship between the levels of EPO without MgO NPs and hemoglobin and GFR, while there was a moderate negative relationship between urea and creatinine. This indicates that when a kidney failure occurs, the hormone erythropoietin decreases, and thus the hemoglobin decreases and anemia occurs [29]. Anemia can occur in patients with DKD when the GFR is < 45 / 1.73 m² due to decrease of EPO production in the kidney and the function to stimulate red blood cell from bone marrow [30]. Fig. 4 shows a moderate positive relationship between EPO with MgO NPs and hemoglobin, and there was no relationship between EPO with MgO NPs and urea, creatinine and GFR in patients with DKD. This means that the EPO increased and its function was improved with the presence of MgO NPs, so the hemoglobin level increased, and the possibility of a relationship with DKD disease disappeared. Patients with DKD often use rHuEPO drug coupled with parenteral iron therapy since iron availability is needed for effective erythropoiesis in conjunction with rHuEPO [31].

Hara et al. [32] observed that anti-EPO receptor antibodies in patients with DKD were associated with low concentrations of EPO hormone, hemoglobin, proteinuria and decrease of GFR. The researchers concluded the anti-EPOR antibodies might be involved in the progression of kidney lesions and the decline erythropoiesis in T2DM patients with CKD [32].
She et al. [33] reported that reduced EPO could be responsible for the deterioration of kidney structure and function. Their study showed that the EPO performed a direct and critical function of renal protection by binding and activating erythropoietin hormone receptor and repressing apoptosis in kidney cells [33].

The protein bonds with nanoparticles increase when the size of these particles decreases due to the increased surface area of nanoparticles. On the other hand, the size of tiny nanoparticles allows them to penetrate almost every part of the human body, including the cells [34]. Fayed et al. [35] observed that injection by EPO loaded with nanoparticles gave high efficacy and a longer effect period in the human body [35]. Behzadi et al. [36] demonstrated it was through hydrophobic interactions that MgO NPs formed complex with human serum albumin molecules. The study of docking based on the size of NPs showed that various linkages between MgO NPs and HSA could be formed and the CD report examined that HSA secondary structure had not been altered by MgO NPs [36].

Alfaro et al. [37] showed that magnesium was an effective drug delivery after coating with polymer polyethylene glycol as the carrier for the 2-methoxyestradiol cancer treatment drug. Small particle size of MgO NPs as shown from TEM was an significant determinant of their biocompatibility which could be model for internalization in the intracellular [37]. Protein therapeutics such as rhuEPO injected in the skin may see internalization and biological activity restricted due to uneasy absorbance into the skin because of the very low permeability; therefore, conjugated nanoparticles with rhuEPO enhanced skin penetration properties and gave transcutaneous protein delivery efficiency [38]. Nanoparticles bind with proteins and receptor proteins of cellular. Such proteins can bind around the entire surface of the NPs [39].

Karimpour et al. [40] showed that the treatment with silver nanoparticles resulted in the increase of progesterone hormone level in the blood. Abdulsattar [41] reported that gold nanoparticles had an influence on sex hormone’s binding to their receptors which led to an increase in the level of the hormone in the blood [41].

To our knowledge, the current study was the first to examine the effects of MgO nanoparticles on erythropoietin hormone. Therefore, the results above have confirmed that it is possible to improve the action of hormone with its receptor, and thus to improve the biochemical and physiological effects of EPO hormone and then reduce the anemia status.

**Conclusions**

In our current study, the effect of MgO NPs has been studied on erythropoietin hormone in vitro of patients with DKD accompanied anemia. It has been shown that there are significant effects on improving and activating erythropoietin hormone action by about 84.8%. There was a positive relationship between the levels of EPO without MgO NPs and hemoglobin and GFR, while there was a moderate positive relationship between urea and creatinine. This indicates that when kidney failure occurs, the hormone erythropoietin decreases, and thus the hemoglobin decreases and anemia occurs. In addition, there was a positive relationship between EPO with MgO NPs and hemoglobin, yet there was no relationship with urea, creatinine and GFR in patients with DKD. This means that the EPO increases and its function improves with the presence of MgO NPs; hence, the hemoglobin level has increased, and the possibility of a relationship with DKD disease disappeared.

The binding of MgO NPs with EPO hormone has an impact not only on the action of EPO hormones but also on the action with its specific receptor and forming receptor-hormone [RH] complexe by improving the binding and interaction between the hormone EPO and its receptor. This increases the concentration and efficiency of the hormone in the blood and thus increases the level of hemoglobin in the blood.

**Acknowledgements**

The authors express their gratitude to M.S.C. Mohamed Ibrahim Hassan for supported in this research.

**Conflict of Interests**

The authors declare that no competing interest exists.

**References**


Copyright © Ameer Radhi Sultan, Fatin Fadhel Mohammed Al-Kazazz, and Asma Hadi Mohammed. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

http://www.nanobe.org